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DESIGN OF RECOMBINANT TENEBRIO MOLITOR ANTIFREEZE PROTEIN FOR 
PURIFICATION USING ELASTIN-LIKE POLYPEPTIDE TAG  
 
JOONGSEOK OH 
 
ABSTRACT 
 
Fusion protein technologies can aid to improve solubility of recombinant protein 
from microorganisms and help recombinant protein purification. Elastin-like 
polypeptides (ELP) as a fusion tag can be utilized to facilitate the purification of 
recombinant proteins because ELP can provide its thermally responsive behavior to ELP 
tagged proteins. An ELP tag can be used as the purification carrier through inverse 
transition cycling (ITC), which is a simple and non chromatographic separation process. 
The purification through ITC can reduce cost and can be quickly performed compared to 
other purification methods. However, we further considered ELP tag removal because it 
may possibly hinder the structure and function of fusion partners (or target proteins). 
Tenebrio molitor antifreeze protein (TmAFP) is an insect AFP and it is classified 
as a hyperactive antifreeze protein because its activity is 10 to 100 times greater than 
AFPs from other sources. TmAFP as a target protein has been purified by cold finger 
purification or chromatographic separation but there are drawbacks.  
The overall goal of this work is to design and implement a strategy for high yield 
of recombinant TmAFP in E. coli through purification using ELP tags. This includes ELP 
tagged TmAFP with a TEV cleavage site. DNA encoding this tag was designed and 
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successfully added to the N-terminus of the TmAFP gene. Then the ELP tags were added 
to the N-terminus of TmAFP and ELP tag DNA was successfully added to N-terminus of 
TEV protease. Of note, ELP[(GVGVP)40] tagged DNA was successfully added to the N-
terminus TEV protease but ELP[(GVGVP)20] tagged DNA was not successfully added. 
Then the ELP tagged fusion proteins were successfully expressed. ELP tagged TmAFPs 
were successfully purified by using ITC while ELP tagged TEV protease was not 
successfully purified by ITC.  
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CHAPTER I 
INTRODUCTION 
 
Recombinant proteins are finding many commercial applications as enzymes, 
bioactive compounds, and therapeutics and their relatively simple synthesis can possibly 
lead to reduced costs for specialty chemicals compared with multistep chemical synthesis 
methods [1] even though these proteins are produced in cells (often in yeast or bacteria) 
and must be purified from cell lysates. Important considerations for successful and 
efficient production of a recombinant protein are its solubility [2] and the existence of 
efficient purification methods that allow easy scale up of recombinant protein production 
[3].  
 It is often desired for biotechnogical purposes (or use) that recombinant proteins 
be soluble when proteins are expressed in bacterial cells [2]. However, recombinant 
proteins are not always soluble and often form inclusion bodies, which are insoluble 
accumulations, secondary to improper folding during protein expression [2].  
Isolated inclusion bodies can be denatured and solubilized by using strong 
denaturants such as urea or guanidine hydrochloride. Then by using methods such as 
dilution, dialysis, diafiltration, gel filtration, or immobilization onto a solid support, the 
denaturant can be removed or decreased in concentration, allowing the protein to be 
refolded (renatured) [79]. According to Maxwell et al, refolding occurred with of 55% of 
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70 insoluble proteins by using denaturing/refolding protein purification [4]. However, 
denaturing inclusion bodies and refolding proteins may not be desired because it might 
result in improper folding, decreased yield, and decreased bioactivity [5]. Also, the 
denaturing and refolding processes can be expensive and time-consuming [5]. 
 According to Schein, most proteins, such as (human interferon-γ and –α) are 
active and soluble with protein expression at ≤ 30 oC in E. coli compared with 37 oC 
because inclusion bodies were formed less from protein expression at low temperatures 
[6]. In fact, high soluble protein yield has been reported from protein expression at 4 oC 
in E. coli [7]. However, lowering the expression temperature does not always improve 
solubility of proteins [8].   
 Fusion protein technologies have become more viable for recombinant protein 
expression and purification because fusion proteins can improve solubility of 
recombinant protein production from microorganisms and help recombinant protein 
purification [5 and 9]. For example, maltose binding protein (MBP) is 42 kDa, and is 
well-known to improve the solubility of recombinant proteins, and can be purified by 
using cross-linked amylase resins, which are not expensive [5]. HisHisHisHisHisHis 
(His6 tag) is common for purifying recombinant proteins because His6 tag can bind to 
Ni(II)-nitrilo triacetic acid (Ni-NTA), which can use immobilized metal affinity tag [9]. 
Multiple fusion techniques, such as the coexpression of MBP and His6 systems, have 
been introduced to improve the solubility of protein expression and in assistance of 
protein purification [10 and 11]. ELP tags are another approach to improve solubility [12] 
and facilitate efficient protein purification [13] and will be discussed in detail later.  
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Fusion order can affect results of protein expression for some constructs [13] 
because it may affect the rate of degradation [9]. N-terminal fusion tags on target proteins 
are known for enhancing the yield and solubility of recombinant proteins [9]. Dyson et al 
found that MBP and Thierodoxin (Trx) showed a great improvement of soluble protein 
production from protein expression when both were placed at either the N-terminal or C-
terminal via fusion [13]. However, MBP alone only enhanced soluble proteins for C-
terminal fusion [13]. 
 Even though fusion tags might improve solubility of recombinant proteins and 
assist in recombinant protein purification, fusion tag removal is an important 
consideration because fusion tags may possibly hinder the structure and function of 
fusion partners (or target proteins) [14]. To remove fusion tags, proteolytic enzymatic 
approaches are broadly used due to their specificity [13]. The cleavage site (or linker) is 
placed in between the fusion tag and fusion partner (or target proteins) [5]. TEV protease 
is often used as a removal tag because TEV provides high site specificity when compared 
to other proteases, such as factor Xa, enteropetidase, and thrombin [15]. 
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1.1 ELP as a purification tag 
Elastin has self aggregation behavior above a certain temperature, which has 
resulted in the development of ELP (elastin-like polypeptide) as an artificial recombinant 
polypeptides [16] designed and synthesized using protein engineering techniques [16 and 
17]. The repeat unit of ELPs is (Gly-Xaa-Gly-Yaa-Pro) or (Yaa-Pro-Gly-Xaa-Gly); Xaa 
can be any amino acid except Proline [16] and Yaa can be any amino acid except Alanine 
[18]. Poly (GVGAP) has shown granular precipitate behavior at an increased temperature 
[18] that may ruin its elasticity and this granular precipitate behavior may be a sign of 
irreversible aggregation [19].   
ELPs exhibit a phase change at a certain temperature, and this behavior of ELP is 
reversible: ELPs are soluble in aqueous solution below their transition temperature (Tt), 
and insoluble above the Tt as evident from solutions becoming turbid [16]. According to 
Urry, (GVGVP)251 was observed to exhibit phase change behavior at a certain 
temperature: (GVGVP)251 aggregated, as evident by its turbidity in aqueous solution 
above 25 oC (Figure 1.1 (A) and (B)) [18]. 
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Figure 1.1. (A) Behavior of (GVGVP)251, Phase separation by Heat. (B) 
Temperature profile, Turbidity vs. Temperature [18]. Reprinted with permission from 
(Urry, D. W. (1997). Physical chemistry of biological free energy transduction as 
demonstrated by elastic protein-based polymers. The Journal of Physical Chemistry B, 
101, 11007-11028.). Copyright (2014) American Chemical Society. 
    
This turbidity at temperatures above Tt is caused by aggregation of ELP 
molecules due to interacting of hydrophobic regions of ELPs [16]. Thermally induced 
conformation change of ELP may play a major role in this phase transition when above 
the transition temperature [20].   
 
1.1.1 The aspects affecting Tt 
The Tt is influenced by concentration, chain length [20 and 21], composition [20], 
salt concentration [22, 23, and 24], and pH [25 and 26]. Chilkoti and Meyer systemically 
showed the transition temperature changes due to concentration and chain length: 
Transition temperatures decreased as ELP concentration and chain length increase 
(Figure 1.2 (A)) [20].  
Also, they mentioned that ELP with more hydrophobic constituents showed a 
lower transition temperature profile; ELP [V1A8G7] has a high Tt, ELP [V5A2G3] has a 
middle Tt, and ELP [V5] has a low Tt because ELP [V5] is the most hydrophobic amongst 
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them (Figure 1.2 (B)) [20]. ELP [VxAyGz-n]: V is Valine, A is Alanine, and G is Glycine. 
x, y, z are ratio x:y:z of V:A:G. n is the number of pentapetides.  
 
 
 
 
 
 
 
 
 
Figure 1.2. (A) Tt vs. Concentration [20].                   (B) Tt vs. ELP chain length [20]. 
Reprinted with permission from (Meyer, D. E. & Chilkoti, A. (2004). Quantification of 
the effects of chain length and concentration on the thermal behavior of elastin-like 
polypeptides. Biomacromolecules, 5, 846-851.). Copyright (2014) American Chemical 
Society. 
  
Salt concentration can further alter transition temperatures [22, 23, and 24]. Tirrell 
et al described the transition temperature of (VPGIG)40 with various salts and their 
concentrations [22]. The phase transition temperature of (VPGIG)40 was decreased by the 
addition of salts and this change is caused by anions (Cl-, SO42-, or I-) [22]. Reguera et al 
discovered the effect of NaCl concentration with a (GVGVP)251 model polymer on 
transition temperature. Transition temperatures decreased as NaCl concentration 
increased (Figure 1.3 (A)) [23].  
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(A)                                                                               (B)    
          
 
 
 
 
 
 
 
 
 
Figure 1.3. (A) Tt of (GVGIP)40 vs. NaCl Concentration [23] and (B) LCST of 
(GVGVP)251 (oC) vs. NaCl Concentration [24]. Reprinted with permission from 
(Reguera, J., Urry, D. W., Parker, T. M., McPherson, D. T., & Rodriguez-Cabello, J. C. 
(2007). Effect of NaCI on the exothermic and endothermic components of the inverse 
temperature transition of a model elastin-like polymer. Biomacromolecules, 8, 354-358.). 
Copyright (2014). American Chemical Society. [23]. Reprinted with permission from 
(Nuhn, H. & Klok, H. (2008). Secondary structure formation and LCST behavior of short 
elastin-like peptides. Biomacromolecules, 9, 2755-2763.). Copyright (2014) American 
Chemical Society. [24]. 
  
Another research group examined LCST (lower critical solution temperature) 
behavior of short ELPs [(GVGVP)5] by NaCl concentration and LCST was decreased 
linearly by increased NaCl concentration (Figure 1.3 (B)) [24].  
The solution pH can affect transition temperature of ELP [25 and 26]. Rodriguez-
Cabello’s lab group demonstrated the pH effect on five different pH-responsive ELPs 
[(PGVGV)2-(PGEGV)-(PGVGV)2]n, n=5, 9, 15, 30, 45 in the pH range of 2.0 to 5.5-6.0, 
and that Tt increased as pH increased [26]. Chilkoti’s lab group examined the effect of 
pH with charged ELP showing that multiple glutamic acid residues can form acidic ELPs 
and histidine residues can form basic ELPs [25]. 
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(A)                                                                      (B) 
  
 
Figure 1.4. Tt vs. Concentration of (A) Acidic ELP pKa=5.29 and (B) Basic ELP 
pKa=6.22 [25]. (A) Ratio V:I:E=1:3:1, 160 pentapeptides (B) Ratio V:H:G:A=1:2:1:1, 
120 pentapetides where V: Valine, I: Isoleucine, E: Glutamic acid, H: Histidine, A: 
Alanine, and G: Glycine. Reprinted with permission from (Mackay, J. A., Callahan, D. J., 
FitzGerald, K. N., & Chilkoti, A. (2010). Quantitative model of the phase behavior of 
recombinant pH-responsive elastin-like polypeptides. Biomacromolecules, 11, 2873-
2879.). Copyright (2014) American Chemical Society. 
  
Transition temperature of acidic ELPs increased with increased pH (Figure 1.4 
(A)) while transition temperature of basic ELPs increased with decreased pH (Figure 1.4 
(B)). Both acid and basic ELPs behaved similarity and transition temperature was 
decreased by the increase of ELP concentration [25]. 
 
1.2 Recombinant protein purification by using ELP tag 
1.2.1 Inverse Thermal Cycling 
 ELPs are thermally sensitive proteins, and ELP gene can be fused genetically to 
target protein DNA. When ELP and the target protein are expressed simultaneously, 
ELPs as fusion tags can facilitate recombinant protein purification. ELP retains its 
thermally response behavior as a fusion protein. Inverse thermal cycling (ITC) is a 
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method where ELP fusion proteins can be purified by the phase change by cycling above 
or below their Tt [52].  
 
 
Figure 1.5. Scheme of ITC purification [52]. (Meyer, D. E., Trabbic-Carlson, K., & 
Chilkoti, A. (2001), Biotechnology Progress, Protein purification by fusion with an 
environmentally responsive elastin-like polypeptide: Effect of polypeptide length on the 
purification of thioredoxin, 17, 720-728.). 
  
ITC is a non-chromatographic separation that is relatively simple [52] because the 
substances, which are in different phases of ELP fusion protein depending on the 
temperature being above or below its Tt, can be separated by changing the temperature 
above and below its Tt  and selecting out the appropriate phase [53]. ELP fusion protein 
phase separates when increasing temperature above its Tt , but ELP fusion protein is 
soluble at temperatures below its Tt [52]. The aggregated ELP fusion protein can be 
resolubilized below its Tt [52]. Ideally, the ELP tag does not alter the stability and 
function of the target protein during ITC [3, 52, and 54]. The ELP tag can be removed 
from the target protein by a proteolytic cleavage sequence between the ELP tag and target 
protein by using a site-specific protease [52].   
 
 
       
10 
 
1.2.2 Advantages of ITC  
 ITC can provide several advantages: ITC does not need expensive 
chromatographic resins and equipment to purify recombinant protein and therefor can 
reduce the cost to scale-up from a laboratory to an industry scale. ITC needs small 
temperature or ionic strength change, is fast and easily performed with several short 
centrifugation [3]. Moreover, ITC is simple and can obtain more than 95% purity within a 
few rounds of ITC. This in comparison to chromatography which might be time 
consuming and may exhibit a limited yield due to the resin’s loading capacity [12]. 
According to Trabbic-Carlson et al, target protein yields from both ITC and IMAC 
(Immobilized Metal Affinity binding Chromatography) by using His tag are similar, but 
IMAC is much less efficient in protein purification. Also, His fusion proteins were less 
stable then ELP fusion protein [55].  
 
1.2.3 Considerations for using ELP tag  
 To use ELP fusion protein for recombinant protein purification, the primary 
considerations are the Tt [3, 20-26, 52, 56, and 57] and fusion order [12]. The Tt of ELP 
fusion protein is desired within a few degrees (oC) higher than protein expression 
temperature: ELP fusion protein remains in a soluble state during protein expression, and 
protein purification is possible with only a small increase of temperature [3]. As 
mentioned earlier, Tt of ELP can be altered by its length and concentration [20 and 21], 
composition [20], salt concentration [22, 23, and 24], and pH [25 and 26], and those 
aspects can also affect Tt of an ELP fusion protein [3].   
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The large molecular weight ELP tag fusion protein is shown to lower Tt when 
compared to that of small molecular weight ELP tag, but small molecular ELP tag is 
known to increase fusion protein yield compared to large molecular ELP tag [3 and 52] 
even though the length (or molecular weight) of ELP might be not related to the 
efficiency of recombinant protein purification [3]. If the Tt of a small molecular weight 
ELP tag fusion protein is too high, the Tt can be lowered by adding NaCl [3 and 52]. 
However, the addition of NaCl does not modify ELP fusion protein behavior [52].  
The surface hydrophobicity of a target protein might shift the Tt of free ELP 
because ELP might interact with the hydrophobic surface of a target protein resulting in a 
lower Tt [56]. The higher hydrophocity of proteins tend to resulting in lower Tt, thus 
imparting a ΔTt effect [56].  
 Chilkoti and Meyer reported that the ELP fusion protein exhibits a Tt shift when 
compared with free ELP but the Tt shift of thioredoxin-ELP fusion protein is much 
smaller versus that of tendamistat and ELP. It might imply that the interaction between 
ELP tag and thioredoxin was not significant compared to tendamistat and ELP. The 
hydrophobic region of tendamistat and ELP tag might interact more thus resulting in a 
greater Tt depression than thioredoxin-ELP fusion protein (Figure 1.6) [3]. 
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Figure 1.6. Turbidity profile, where (♦) free ELP; (▲) thioredoxin-ELP; (○) 
thioredoxin-ELP-tendamistat; (◊) ELP-tendamistat; and (□) thioredoxin-ELP [3]. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Biotechnology, Meyer, 
D. E. & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with 
thermally-responsive polypeptide. 17, 1112-1115, Copyright (2014). 
   
Lim et al stated that cationic ELP could interact with negatively charged target 
proteins and described this interaction as ‘greater salt sensitivity’ of cationic ELP. 
Adding a small amount of NaCl to small cationic ELP resulted in decreased phase 
transition temperature [57]. Also, they suggested that anionic ELP with cationic target 
protein might show similar behavior [57].  
   Fusion order is where a fusion tag is placed on either the N-terminal or C-terminal 
of a target protein. Fusion order has been shown to affect the solubility, expression level, 
or activity of a fusion protein in some cases [12]. According to Christensen et al, most 
protein-ELP showed higher expression level (with increased yield), and better specific 
activity than ELP-protein: Protein-ELP is a C-terminal fusion of ELP, and ELP-protein is 
an N-terminal fusion of ELP to protein (Figure 1.7) [12]. Even though ELP-protein 
fusion (or N-terminal fusion to protein) showed lower level of soluble protein expression, 
this N-terminal fusion has been reported to have little inclusion body formation. This is 
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due to an ELP tag in N-terminal fusion might help mis-folded fusion protein achieve a 
soluble state [12]. Mis-folded proteins often are aggregated and become insoluble [12].    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Fusion protein yield depending on fusion order; BFP is blue fluorescent 
protein, CAT is chloramphenicol acetyltransferase, Trx is thioredoxin, and IL1Ra is 
interleukin-1 receptor antagonist [12]. (Christensen, T., Amiram, M., Dagher, S., Trabbc-
Carlson, K., Shamji, M. F., Setton, L. A., and Chilkoti, A. (2009), Protein Science, 
Fusion order controls expression level and activity of elastin-like polypeptide fusion 
proteins, 18, 1377-1387.). 
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1.3 TmAFP  
1.3.1 Antifreeze protein 
 Many living creatures survive in extreme environments by adaptative behaviors. 
Subzero temperatures is a harsh environment but many organisms have adapted to 
survive in a subzero habitat [27]. Ice formation within cells can cause the interruption of 
structural organization resulting in cell death [28]. Some organisms, which are freeze 
tolerant, have adapted to a subzero environment by synthesizing special substances that 
prevent ice formation within their bodies, such as antifreeze protein (AFP) otherwise 
known as thermal hysteresis proteins [27].  
 AFPs are capable of binding to ice crystals which lead to a lower melting point of 
ice [29]. AFPs are capable of inhibiting growth and recrystallization of ice crystal within 
an organisms body in the subzero temperature because AFPs have ice-binding domains 
[29]. In this manner, the interaction between AFPs and ice crystal can cause a non-
equilibrium freezing-point depression, which is the difference between the melting point 
and freezing point of ice. This difference is called thermal hysteresis and can be used for 
measuring activity of AFP [30]. AFPs have different behavior compared with other 
chemical antifreeze materials because AFPs exhibit non-colligative freezing point 
depression due to the interaction between AFPs and ice crystals [30].  
 Antifreeze proteins are divided into two major classes, antifreeze proteins and 
antifreeze glycoproteins (AFGP) [27]. Antifreeze proteins have been found in several 
different species: fish [31-38], insects [37, 39-42, 50, and 51], plants [42 and 44], and 
other organisms [47-49]. 
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 Fish AFPs are classified as Type I [31 and 32], II [33 and 34], III [35], IV [36], 
and AFGP [37 and 38]. Type I APFs were found in plasma and skin tissues of winter 
flounder and the sculpins which live in polar oceans [32].Type I AFPs are alanine rich 
and are mostly single α-helical elongated proteins [32], and have a molar mass of 3.3 – 
4.5 kDa [31]. Type II AFPs are found in sea raven (Hemitripterus americanus), herring 
(Clupea hargengus harengus), smelt (Osmerus merdox) [33], and long snout poacher 
(Brachyopsis rostratus) [34]. Type II AFPs are globular shaped, have a molar mass of 14-
24 kDa, and are cysteine rich proteins [34]. Type II AFPs are categorized by the Ca2+ 
dependence of their antifreeze activity; herring and smelt AFPs are Ca2+ dependent, and 
sea raven and long snout poacher AFPs are Ca2+ independent [34]. Type III AFPs were 
first found in the ocean pout (Macrozoarces americanus), and are globular shaped 
proteins with a 7 kDa molecular weight [35]. Type IV AFPs are found in longhorn 
sculpin (LHS) and shorthorn sculpin (SHS); type IV AFPs from LHS are 12.3 kDa, 
Glutamine rich, with an α-helix structure, and type IV AFPs from SHS are 12.2 kDa, and 
shown to have 87% similarity to that of LHS [36]. Also, LSH and SHS can both produce 
type I and type IV AFPs which might enable them respond quickly to temperature 
changes as an evolutionary adaption [36].  
AFGPs are found in the blood serum of Antartic notothenoids and Artic cod [37]. 
AFGP have a molar mass of 2.6 kDa to 33.7 kDa, and have an (Ala-Ala-Thr)n repeat unit 
[37]. Arctic psychrophilic yeast also contain AFGP that are 26 kDa in size [38]. 
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(A)                                                                (B) 
  
Figure 1.8. (A) Fish AFP structures and model [40] and (B) Antifreeze glycoprotein 
structure [37]. (Graether, S. P. & Sykes, B. D. (2004), European Journal of 
Biochemistry, Cold survival in freeze-intolerant insects: The structure and function of β-
helical antifreeze proteins, 271, 3285-3296.) [40]. (Harding, M. M., Anderberg, P. I., & 
Haymet, A. D. J. (2003), European Journal of Biochemistry, ‘Antifreeze’ glycoproteins 
from polar fish, 270, 1381-1392.) [37].  
 
Two major different insect antifreeze proteins have been vigorously studied, the 
spruce budworm (Choristoneura fumiferama)-sbwAFP or CfAFP and yellow mealworm 
(Tenebrio moliter) – TmAFP [39 and 40]. SbwAFP is a left handed, β-helix protein with 
15 residues per coil, 4 disulfide bonds, TXT (Thr-X-Thr, X can be any amino acid) repeat 
unit, and are a triangular prism shape [40]. TmAFP is a right handed,  β-helix protein 
with 12 residues per coil, 8 disulfide bonds, less than 9 kDa, contain a TCTxSxxCxxAx 
(x can be any amino acid) repeat unit [39], with a flattened cylinder shape, and is a more 
regular structure than sbwAFP [40]. 
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(A)                                                                    (B)  
     
Figure 1.9. (A) Structure of sbwAFP [41] and (B) Structure of TmAFP [42]. 
Reprinted by permission from Macmillan Publishers Ltd: Nature, Graether, S. P., Kulper, 
M., Gagné, S. M., Walker, V. K., Jia, Z., Sykes, B. D., and Davies, P. L. (2000). β-Helix 
structure and ice-binding properties of a hyperactive antifreeze protein from an insect, 
406, 325-328., copyright (2014) [41]. (Marshall, C. B., Daley, M. E., Graham, L. A., 
Sykes, B. D., and Davies, P. L. (2002), FEBS Letters, Identification of the ice-binding 
face of antifreeze protein from Tenebrio molitor, 529, 261-267.) [42]. 
 
 The TmAFP and sbwAFP are classified as hyperactive antifreeze proteins because 
the activities of TmAFP and sbwAFP are 10 to 100 times greater than of fish antifreeze 
protein [50], which is attributed to the fact that they can bind to both the basal and prism 
plane of ice crystals [40 and 51]. 
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1.4 TEV protease as a cutter 
1.4.1 TEV protease 
 TEV protease is commonly used for tag removal [58]. Dougherty and Parks 
mentioned that the 27 kDa of TEV protease can be expressed as a recombinant TEV 
protease protein in E. coli [59].  
The optimal temperature of TEV protease activity is 30 oC [15 and 60], and TEV 
protease activity is decreased above 34 oC because of possible unfolding of the protease 
[15]. TEV protease activity is decreased with increasing NaCl concentration [15].  
 
Figure 1.10. (A) Optimal Temperature, 30 oC is the optimal temperature of TEV 
protease activity (B) Optimal Salt Concentration, TEV protease activity decreased by 
addition of NaCl. The figures were modified from the original pictures [15]. Reprinted 
from Protein Expression and Purification, 38, Nallamsetty, S., Kapust, R. B., Tözsér, J., 
Cherry, S., Tropea, J. E., Copeland, T. D., and Waugh, D. S. (2004), Efficient site-
specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and 
in vitro. 108-115, Copyright (2014), with permission from Elsevier.  
    
   TEV protease is becoming more common for tag removal by cleavage [58] 
because TEV protease has several advantages [61, 62, and 63]. TEV protease can be 
expressed in E. coli which can increase its yield and improve its solubility. The increase 
in high yield of TEV protease by modifications of its expression condition may result in 
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cheaper production costs [61]. Phan et al reported that the structure of TEV protease 
leads to highly restricted specificity for the TEV recognition sequence [62]. The crystal 
structure of TEV protease is comprised of two-domain antiparellel β-barrel fold (which is 
found on trypsin-like serine protease) with His 46, Asp 81, and Cys 151 of catalytic triad 
residue placed in the contact face between two domains [62]. Also, the extended β-sheet 
interactions between TEV protease and its substrate backbone were observed [62]. TEV 
protease is active in various buffers [63] even though its activity was affected by NaCl 
[15] and some detergents [64]. Mohanty et al found that some detergents could reduce the 
activity of TEV protease [64]. However, Sun et al discovered that the cleavage activity of 
TEV protease showed high activity in four commonly used elution buffers and tolerance 
to various detergents and denaturants [63].   
 
 1.4.2 TEV protease recognition site 
 According to Carrington and Dougherty, the recognition site of TEV protease was 
known as EXXYXQS or EXXYXQG (Glu-Xaa-Xaa-Tyr-Xaa-Gln-Ser or Gly, where X 
or Xaa can be any amino acid), which is cleaved between Gln and Ser or Gly [65]. The 
position of residues were named Glu(P6)-Xaa(P5)-Xaa(P4)-Tyr(P3)-Xaa(P2)-Gln(P1)-
Ser or Gly (P1') [65]. Subsequently, research by Tȍzsѐr et al discovered the followings: 
First, Gln in P1 position is required. Second, Gly, Ser, Ala are small aliphatic resides 
which showed strong preference in P1' position. Third, Phe in P2 and Glu in P6 showed 
strong preference. Fourth, P5 residue is not a significant determinant. Fifth, Leu, Ile, and 
Val are preferred in the P4 position because they are all branched-chain aliphatic amino 
acids [66]. Also, Leu is very favorable in P4 position because of the hydrophobic 
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interaction between TEV protease and its substrate [66]. The most prevalent and used 
recognition sequence of TEV protease is known as ENLYFQS(Glu-Asn-Leu-Tyr-Phe-
Gln-Ser) or ENLYFQG(Glu-Asn-Leu-Tyr-Phe-Gln-Gly) [67]. The study of P1' position 
showed that Ser and Gly residue in recognition sequence of TEV protease could be more 
catalytically efficient due to their paucity of side chain residues [67]. 
 
1.4.3 Issues of TEV protease expression  
TEV protease has been reported to have two major issues in recombinant protein; 
autolysis [68, 69, and 70] and low solubility [61, 71, and 72]. 
 Parks et al discovered that the recombinant fusion protein (~28 kDa) with a 
seven-His tag and TEV protease showed self-cleavage at a specific internal site, which 
was shown by an excised C-terminal 24 amino acid region of TEV protease amino acid 
sequences. This truncated protease was much less active than the full, untruncated TEV 
protease [68]. Since the C-terminal residues 235-242 of TEV protease are involved in the 
binding of TEV protease recognition site to its substrate, the activity of TEV protease 
would be reduced if the self-cleavage (or auto cleavage) takes places between its residue 
218 and 219 [69]. Kapust et al discovered that some mutations of amino acid in certain 
residues of TEV protease resulted in reduced autolysis. The residue 219 S was replaced 
with D, E, V, and P (which were S219D, S219E, S219V, and S219P respectively), and 
the residue 217 F was replaced with K (which was F217K) [70]. S219V showed ~100 
fold slower rate of truncated protease formation than that of wild -type protease, and 
S219V was more catalytically efficient than wild-type protease [70].  
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  Another issue is that TEV protease expression results in low solubility of 
recombinant protein [71]. In silico design by using the PoPMuSic program, the mutations 
in both L56V and S135G (eg., V instead of L at 56, and G instead of S at 135) showed 
improvement of the solubility of TEV protease with mutations leading to enhanced 
surface polarity of TEV protease (Figure 1.11) [71] .  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Solubility vs. TEV Variants [71]. (Cabrita, L. D., Gilis, D., Robertson, A. 
L., Dehouck, Y., Rooman, M., and Bottomley, S. P. (2007), Protein Science, Enhancing 
the stability and solubility of TEV protease using in silico design, 16, 2360-2367.). 
 
 
 According to Fang et al, the TEV protease expression showed little improvement 
of soluble protein production at 28 oC versus 37 oC, but both co-expression of fusion 
protein (His-TEV protease) and the lowering expression temperature showed a drastic 
improvement of soluble fusion protein production at 28 oC versus 37 oC. It seemed that 
this co-expression and lower expression temperature work synergistically together [61]. 
In addition, MBP (maltose-binding protein), which is a fusion tag and known as 
solubility improvement of its fusion partner, is fused to TEV protease, and the fusion 
protein’s solubility is enhanced even more compared to other solubility enhancer fusion 
tags because MBP may contribute to the appropriate folding of TEV protease [72]. 
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1.5 The goal of this work 
TmAFP as a target protein was modified previously by adding a trimer forming 
domain and was purified by cold finger purification [39 and 73]. Other researchers 
modified it using His6 tag for purification by chromatographic separation [39]. However, 
the cold finger purification takes time to purify AFP, more than 8-16 hours [74] and the 
chromatographic separation is not easy to scale up [3].  
 The overall goal of this work was to design and implement a strategy for high 
yield of recombinant TmAFP in E. coli through purification using ELP tags. This strategy 
included TEV cleavage sites and ELP tags that were successfully added to the N-
terminus of TmAFP. Then ELP tags were added to the N-terminus of TmAFP in pET20b 
and ELP tagged TmAFP fusion proteins which were successfully expressed in Origami 
host cells. The ELP tag DNA were successfully added to the N-terminus of TEV protease 
in pET20b and ELP tagged TEV protease fusion proteins were successfully expressed in 
BL21* host cells. ELP tagged TmAFPs were successfully purified by using ITC while 
ELP tagged TEV protease was not successfully purified by using ITC. ELP tags were 
functional through ITC purification and appeared to aid in target protein purification. 
This purification method may be applicable for scale-up mass production of recombinant 
TmAFP.      
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Synthesis of plasmid DNAs 
In order to accomplish the goal of this work, the genes of ELP tags and TEV 
protease cleavage sites were sequentially added using molecular biology techniques to 
the N-terminus of TmAFP gene resulting in ELP-TEVG-TmAFP and ELP-TEVS-
TmAFP. In addition, ELP tags were added to N-terminus of TEV Protease resulting in 
ELP-TEV protease. 
 
2.1.1 Design and synthesis of TEV protease cleavage site: TEVG (ENLYFQG) and TEVS 
(ENLYFQS) 
 In order to remove the ELP tag in the final protein, TEV protease cleavage sites 
were engineered in between ELP and TmAFP. The common cleavage sites of TEV 
protease were reported as amino acid sequences of ENLYFQG and ENLYFQS [67]. To 
synthesis DNA for TEV protease cleavage sites, a set of primers were designed to be 
compatible with restriction enzyme cut sites of NdeI, PflMI, and BglI, which are 
commonly used in our lab for DNA synthesis.  
 TEVG forward and TEVG reverse primers were designed and were ordered from 
Invitrogen. 
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TEVG forward primer (5’ to 3’) 
TATGGGCCACGGCGTGGAAAACCTGTACTTCCAGGGGCCGGGC 
TEVG reverse primer (5’ to 3’) 
CGGCCCCTGGAAGTACAGGTTTTCCACGCCGTGGCCCA 
 
 TEVS forward and TEV S reverse primers were designed and were ordered from 
Invitrogen. 
TEVS forward primer (5’ to 3’) 
TATGGGCCACGGCGTGGAAAACCTGTACTTCCAGTCGCCGGGC 
TEVS reverse primer (5’ to 3’) 
CGGCGACTGGAAGTACAGGTTTTCCACGCCGTGGCCCA 
 
 The annealing process of each set of forward and reverse primer were performed 
to synthesize TEVG and TEVS double stranded DNA by heating to 95 oC and cooling 
gradually in a thermo cycler (Thermo Electron Corp.). The annealing process protocol is 
described in Appendix (A.1). The following double stranded DNA sequences can be 
obtained by the annealing process;  
ATG is the start DNA code. 
TEVG (TEV protease cleavage site, ENLYFQ/G) 
 NdeI       PflMI     TEV protease cleavage site BglI(SfiI)   
5’ ^TATGGGCCACGGC^GTG GAA AAC CTG TAC TTC CAG GGGCCGGGC^ 3’           
3’    ACCCGGTG^CCGCAC CTT TTG GAC ATG AAG GTC CCCGGC^    5’ 
                      Glu Asn Leu Tyr Phe Gln Gly 
       E   N   L   Y   F   Q   G 
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TEVS (TEV protease cleavage site, ENLYFQ/S) 
 NdeI        PflMI    TEV protease cleavage site    BglI 
5’ ^TATGGGCCACGGC^GTG GAA AAC CTG TAC TTC CAG TCGCCGGGC^ 3’           
3’    ACCCGGTG^CCGCAC CTT TTG GAC ATG AAG GTC AGCGGC^    5’ 
                      Glu Asn Leu Tyr Phe Gln Ser   
                                                       E   N   L   Y   F   Q   S 
 
2.1.2 Construction of ELP-TEVG-TmAFP and ELP-TEVS-TmAFP DNA 
Genes encoding ELP[(GVGVP)20]-TEVG-TmAFP, ELP[(GVGVP)20]-TEVS-
TmAFP, ELP[(GVGVP)40]-TEVG-TmAFP, and ELP[(GVGVP)40]-TEVS-TmAFP were 
prepared. The TmAFP-pET25b plasmid was obtained in our lab.  
 
The DNA sequences for TmAFP (5’ to 3’), 252 bps: 
CAGTGCACCGGTGGTGCTGACTGCACCAGCTGCACCGCTGCTTGCACCGGTTGC
GGTAACTGCCCGAACGCTGTTACTTGCACTAACAGCCAGCACTGCGTTAAAGCT
ACCACCTGCACCGGTAGCACCGACTGCAACACCGCTGTTACCTGCACTAACTCT
AAAGACTGCTTCGAAGCTCAGACCTGCACCGACTCTACCAACTGCTACAAAGCT
ACCGCTTGCACCAACTCTACCGGCTGCCCGGGTCAC 
 
The amino acid sequences for TmAFP:  
QCTGGADCTSCTAACTGCGNCPNAVTCTNSQHCVKATTCTGSTDCNTAVTCTNS
KDCFEAQTCTDSTNCYKATACTNSTGCPGH 
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 PflMI, a restriction enzyme, was commonly used in our lab for DNA synthesis. 
Since PflMI cut site was discovered in the middle of pET25b expression vector, it can 
lead to an additional PflMI cut site which could lead to inability to use PflMI for further 
DNA synthesis. Therefore, pET25b was eventually replaced by pET20b for this research. 
TmAFP-pET25b plasmid was double digested by the restriction enzymes NdeI 
and EcoRI that was used as an insert for ligation. The 40 µl of reaction mixture was 
added with 2 µl NdeI, 2 µl EcoRI (New England Biolabs), 15 µl DNA, 4 µl 10x buffer 
EcoRI (New England Biolabs), and 16 µl Nuclease free water. The reaction mixture was 
incubated in a 37 oC water bath for 3 hours. pET20b plasmid was obtained in our lab and 
also double digested with NdeI and EcoRI that was used as a vector. The 40 µl of 
reaction mixture was added with 2 µl NdeI, 2 µl EcoRI, 15 µl DNA, 4 µl 10x buffer 
EcoRI, and 16 µl Nuclease free water. The reaction mixture was incubated in a 37 oC 
water bath for 3 hours. The double digested DNA was mixed with 6x load dye 
(Promega), and then loaded on a 1.5 % agarose gel with TAE buffer at 80V for 40 
minutes. The protocol of preparation of 1.5 % agarose gel is described in Appendix (A.2). 
Under UV light, the gel (the size on position) was cut out, and then the gel was purified 
by using a gel extraction kit (Qiagen). Then, TmAFP insert and pET20b vector were 
ligated together. The 21 µl of ligation mixture contained 1 µl vector DNA, 3 µl insert 
DNA, 10 µl quick ligase buffer (New England Biolabs), 1 µl quick ligase (New England 
Biolabs), and 6 µl nuclease free water. The ligation mixture was kept in a 5 min 
incubation at room temperature. The ligated DNA was inserted into BL21* competent 
cells. BL21* competent cells from -80 oC freezer were thawed out on ice. The 10 µl of 
ligation mixture and 50 µl of BL21* competent cells were mixed and heat shocked for 2 
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minutes at 37 oC. It was then incubated at 37 oC for 1 hour with addition of 950 µl of LB 
media. The 350 µl of transformation mixture was then placed on a LB agar plate with 
ampicillin (100 µg/ml) from Fisher Scientific. The LB agar plates were placed in an 
incubator at 37 oC for overnight. When the colonies were observed, the colonies were 
carefully selected and transferred into 6 ml of LB medium with ampicillin. The cultures 
were incubated at 37 oC with shaking 300 rpm overnight. The frozen stocks were made 
with the mixture of 400 µl of 50 % glycerol and 500 µl of bacteria cell culture, and the 
frozen stocks were stored in a -80 oC freezer. The plasmid DNA was isolated from an 
overnight culture by using a miniprep kit (Qiagen). The isolated plasmid DNA was 
screened with PCR screening via a thermo cycler (Thermo Electron Corp.) to determine 
whether the ligation was successful or not. The PCR was performed with a T7 forward 
primer and T7 reverse primer. The PCR protocol for screening is described in Appendix 
(A.3). After PCR was performed, the PCR samples were loaded onto the agarose gel as 
previously described. If ligation was successful, the plasmid DNA (vector and insert) was 
located on a higher position as much as an insert size, versus a vector only plasmid. 
Isolated DNA from positive screens was sent to Genomic Lab at the Cleveland Clinic 
Foundation (CCF) for DNA sequencing. These isolated DNAs were confirmed to be 
TmAFP-pET20b plasmids. 
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Figure 2.1. Schematic diagram of the synthesis of TmAFP-pET20b. 
 
TmAFP-pET20b plasmid was double digested by the restriction enzymes NdeI 
(New England Biolabs) and SfiI (New England Biolabs) sequentially and used as a vector 
for ligation. The 50 µl of reaction mixture contained 2 µl NdeI, 10 µl DNA, 5 µl 10 
buffer 2 (New England Biolabs), and 31 µl Nuclease-free water. The reaction mixture 
was incubated in a 37 oC water bath for 2 hours. Then, 2 µl SfiI was added into the 
reaction mixture, and incubated in a 55 oC dry bath for 2 additional hours. The double 
digested DNA was then loaded onto the agarose gel and purified by using a gel extraction 
kit (Qiagen). Ligation of TEVG or TEVS inserts and TmAFP-pET20b vector was 
performed. Transformation into BL21* competent cells was carried out. The colonies 
were carefully selected and grown in LB medium with ampicillin. The frozen stocks were 
made and stored. The plasmid DNA was isolated and screened with PCR screening. The 
isolated DNA was sent to the Genomic Lab at the Cleveland Clinic Foundation (CCF) for 
DNA sequencing. 
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Figure 2.2. Schematic diagram of the synthesis of TEVG-TmAFP and TEVS-
TmAFP. 
 
The neutral ELPs, which were (GVGVP)20 and (GVGVP)40, were chosen and 
ELP plasmids were obtained in our lab. ELP-pET20b plasmids were isolated from 
overnight cultures by using a miniprep kit (Qiagen). ELP plasmids were double digested 
with NdeI and BglI as inserts for ligation. The 40 µl of double digestion mixture 
contained 2 µl NdeI, 2 µl BglI, 4 µl 10x buffer 3 (New England Biolabs), 17 µl nuclease 
free water, and 15 µl DNA. The reaction mixture was incubated in a 37 oC water bath for 
3 hours. Also TEVG-TmAFP and TEVS-TmAFP in pET20b plasmid were double 
digested with NdeI and PflMI for vectors. The 40 µl of reaction mixture contained 2µl 
NdeI, 2 µl PflMI, 0.4 µl 100x BSA (New England Biolabs), 4 µl 10x buffer 2 (New 
England Biolabs), 16.6 µl nuclease free water, and 15 µl DNA. The double digestion 
mixture was incubated in a 37 oC water bath for 3 hours. The double digested DNA for 
vectors and inserts were loaded onto the agarose gel, and purified by using a gel 
extraction kit (Qiagen). The ligation and transformation were performed by the 
previously mentioned protocols. The colonies were picked and grown in LB media with 
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ampicillin. The frozen stocks were made and stored in a -80 oC freezer. The plasmid 
DNA was isolated and PCR screening was carried out. The isolated DNA was sent to the 
Genomic Lab at the Cleveland Clinic Foundation for DNA sequencing. 
 
Figure 2.3. Schematic diagram of the synthesis of ELP-TEVG-TmAFP and                                          
ELP-TEVS-TmAFP. 
  
Finally, ELP-TEVG-TmAFP and ELP-TEVS-TmAFP DNA plasmids were 
transformed into origami competent cells since origami host cells can facilitate forming 
the proper pairing of disulfide bonds in TmAFP during protein expression [39]. 
 
 
2.1.3 Construction of ELP-TEV Protease DNA 
 ELP[(GVGVP)20]-TEV Protease and ELP[(GVGVP)40]-TEV Protease were 
synthesized. TEV Protease plasmid DNA, Plasmid 8827: pRK793 was ordered from 
Addgene. 
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DNA sequences of TEV Protease, 708bp 
GGAGAAAGCTTGTTTAAGGGGCCGCGTGATTACAACCCGATATCGAGCACCATT
TGTCATTTGACGAATGAATCTGATGGGCACACAACATCGTTGTATGGTATTGGA
TTTGGTCCCTTCATCATTACAAACAAGCACTTGTTTAGAAGAAATAATGGAACA
CTGTTGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAACACCACGACTTTG
CAACAACACCTCATTGATGGGAGGGACATGATAATTATTCGCATGCCTAAGGAT
TTCCCACCATTTCCTCAAAAGCTGAAATTTAGAGAGCCACAAAGGGAAGAGCGC
ATATGTCTTGTGACAACCAACTTCCAAACTAAGAGCATGTCTAGCATGGTGTCA
GACACTAGTTGCACATTCCCTTCATCTGATGGCATATTCTGGAAGCATTGGATT
CAAACCAAGGATGGGCAGTGTGGCAGTCCATTAGTATCAACTAGAGATGGGTTC
ATTGTTGGTATACACTCAGCATCGAATTTCACCAACACAAACAATTATTTCACA
AGCGTGCCGAAAAACTTCATGGAATTGTTGACAAATCAGGAGGCGCAGCAGTGG
GTTAGTGGTTGGCGATTAAATGCTGACTCAGTATTGTGGGGGGGCCATAAAGTT
TTCATGGTGAAACCTGAAGAGCCTTTTCAGCCAGTTAAGGAAGCGACTCAACTC
ATGAAT 
 
Amino Acid Sequences of TEV Protease (236 aa): 
GESLFKGPRDYNPISSTICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGT
LLVQSLHGVFKVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQREER
ICLVTTNFQTKSMSSMVSDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVSTRDGF
IVGIHSASNFTNTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLWGGHKV
FMVKPEEPFQPVKEATQLMN 
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The restriction enzyme cut sites were checked. 
 
Figure 2.4. Restriction enzyme recognition site map of TEV protease by using NEB 
cutter 2.0. Retrieved from New England Biolabs web site                    
http://tools.neb.com/NEBcutter2/index.php [75].           
                                                                       
As shown in the above restriction enzyme recognition site map, a NdeI cut site is 
located in the middle of the TEV protease DNA sequence (bolded DNA sequences). NdeI 
is commonly used in our lab when adding fusion tags. Therefore, the NdeI cut site was 
removed from the original DNA of TEV protease by mutation in order to not excise an 
area of interest within the TEV protease DNA sequences when adding the fusion tags. 
Compared with the original TEV protease, the new DNA sequences were different, but 
the amino acid sequence coded for was the same as that of the original TEV protease.  
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Figure 2.5. Schematic diagram of the synthesis of the mutated TEV Protease insert.  
 
The NdeI cut site was replaced by a DraIII cut site because DraIII was not 
commonly used in our lab. Also, PflMI cut site needed to be modified because DraIII 
recognizes the PflMI cut site that was used in our lab. For this mutational process, two 
pairs of DNA primers were designed, and these primers were ordered from Invitrogen. 
The original DNA of TEV protease was extracted by PCR amplification using a thermo 
cycler (Thermo Electron Corp.) using the two pairs of primers. Two parts were prepared 
from the original DNA of TEV protease sequentially (Appendix A.3); labeled as 1N (Part 
I) and 2N (Part II). For 2N (Part II), TEV Dra forward and TEV Bgl reverse primers were 
used: 
TEV Dra forward primer (5' to 3') 
TTTGGGCATATGGGGCCACAACGTGAAGAGCGTATATGTCTTGTGAC 
TEV Bgl reverse primer (5' to 3') 
GACTCAACTCATGAATTAATGACTGCCAGGCTGGCCCTCTT 
  
 
       
34 
 
For 1N, TEV NoDra forward and TEV Dra reverse primers were used: 
TEV NoDra forward primer (5' to 3') 
TTTTTTCATATGGGCCAGGGCGTGGGAGAAAGCTTG 
TEV Dra reverse primer (5' to 3') 
TTCCTTCACGTTGTGGCTCTCTAAATTTCAGC 
 
 The PCR products were run on an agarose gel and purified using a gel extraction 
kit (Qiagen). Both 1N and 2N were single digested with Dra III. Each 40 µl of reaction 
mixture contained 4 µl 10x buffer 3, 0.4 µl 100x BSA, 18.6 µl nuclease free water, and 2 
µl DraIII (New England Biolabs). The reaction mixtures were incubated in a 37 oC water 
bath for 3 hours followed by gel purification. Purified 1N and 2N were ligated with E. 
coli DNA ligase. The 20 µl of ligation mixture contained 5 µl of 1N, 5 µl of 2N, 2 µl E. 
coli DNA ligase buffer (New England Biolabs), 1 µl E. coli DNA ligase (New England 
Biolabs), and 7 µl nuclease free water. The ligation mixture was incubated in a 4 oC cold 
room for 1 hour, and then heat inactivation was carried out by using a thermo cycler 
(Thermo Electron Corp.) for 20 minutes at 65 oC.  
 
 The expected DNA sequences of the mutated TEV protease (5’ -> 3’), 708bp 
GGAGAAAGCTTGTTTAAGGGGCCGCGTGATTACAACCCGATATCGAGCACCATT
TGTCATTTGACGAATGAATCTGATGGGCACACAACATCGTTGTATGGTATTGGA
TTTGGTCCCTTCATCATTACAAACAAGCACTTGTTTAGAAGAAATAATGGAACA
CTGTTGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAACACCACGACTTTG
CAACAACACCTCATTGATGGGAGGGACATGATAATTATTCGCATGCCTAAGGAT
TTCCCACCATTTCCTCAAAAGCTGAAATTTAGAGAGCCACAACGTGAAGAGCGT
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ATCTGCCTTGTGACAACCAACTTCCAAACTAAGAGCATGTCTAGCATGGTGTCA
GACACTAGTTGCACATTCCCTTCATCTGATGGCATATTCTGGAAGCATTGGATT
CAAACCAAGGATGGGCAGTGTGGCAGTCCATTAGTATCAACTAGAGATGGGTTC
ATTGTTGGTATACACTCAGCATCGAATTTCACCAACACAAACAATTATTTCACA
AGCGTGCCGAAAAACTTCATGGAATTGTTGACAAATCAGGAGGCGCAGCAGTGG
GTTAGTGGTTGGCGATTAAATGCTGACTCAGTATTGTGGGGGGGCCATAAAGTT
TTCATGGTGAAACCTGAAGAGCCTTTTCAGCCAGTTAAGGAAGCGACTCAACTC
ATGAAT  
 
 
The amino acid sequences of the mutated TEV Protease (236 aa): 
GESLFKGPRDYNPISSTICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGT
LLVQSLHGVFKVKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQREER
ICLVTTNFQTKSMSSMVSDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVSTRDGF
IVGIHSASNFTNTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLWGGHKV
FMVKPEEPFQPVKEATQLMN 
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The restriction enzyme cut sites of the mutated TEV protease were checked. 
 
 
Figure 2.6. Restriction enzyme recognition site map of the mutated TEV protease by 
using NEB cutter 2.0. Retrieved from New England Biolabs web site                     
http://tools.neb.com/NEBcutter2/index.php [75]. 
 
The ligation of 1N and 2N was amplified by PCR (Appendix A.3) using TEV 
NoDra forward and TEV Bgl reverse primers. The PCR product was gel purified. The 
mutated TEV protease was double digested with NdeI and BglI. The double digested 
TEV protease DNA was gel purified for insert. pET20b SfiI plasmid was double digested 
with NdeI and SfiI, and gel purified for vector. The ligation between mutated TEV 
protease insert and pET20b SfiI vector was carried out followed by transformation into 
BL21* competent cells. The plasmid DNA was isolated as previously described, and 
PCR screening and DNA sequencing were performed.  
 
 
 
 
 
       
37 
 
 
Figure 2.7. Schematic diagram of the synthesis of TEV Protease-pET 20b Sfi I. 
 
The ELP inserts (GVGVP)20 and (GVGVP)40 were prepared. TEV Protease-pET 
20b Sfi I vector was also prepared. TEV Protease-pET 20b Sfi I plasmid was double 
digested with NdeI and PflMI. The double digested DNA was loaded onto the gel and 
purified. ELP inserts and TEV Protease-pET 20b Sfi I vector were ligated and 
transformed into BL 21* competent cells. The frozen stocks were made and stored in a -
80 oC freezer. The isolated plasmid was PCR screened and DNA sequences were 
obtained from the Genomic Lab at the Cleveland Clinic Foundation. 
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Figure 2.8. Schematic diagram of the synthesis of ELP-TEV Protease. 
       
2.2 Protein Expression 
2.2.1 ELP-TEVG-TmAFP and ELP-TEVS-TmAFP in Origami host cell 
 ELP-TEVG-TmAFP-pET20b and ELP-TEVS-TmAFP-pET20b in Origami host 
cell were used for protein expression. The cells from a frozen stock at -80 oC were grown 
in 10 ml LB media with ampicillin (100 µg/ml) at 37 oC with shaking 300 rpm. The 10 
ml overnight cultures were inoculated and grown in 1 L LB medium with ampicillin (100 
µg /ml). Cell growth was monitored by optical density measured at 600 nm wave length 
(OD600) using a UV-Vis spectrophotometer (Thermo Scientific Biomate 3). When the 
OD600 reached 0.6, 0.5 mM of Isopropyl-β-D-thiogalatopyranoside (IPTG) from Promega 
was added to each 1 L culture for induction. The incubation was continued for 48 hours 
more at 15 oC with concurrent shaking at 300 rpm. 
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2.2.2 ELP-TEV protease in BL21* host cell 
 The ELP-TEV protease in pET20b expression vector was used for protein 
expression. The cells from a frozen stock at -80 oC was grown in 10 ml LB media at 4 oC 
cold room with ampicillin (100 µg/ml) at 37 oC with shaking at 300 rpm. The 10 ml 
overnight cultures were inoculated and grown in 1 L LB medium with ampicillin (100 µg 
/ml) to OD600nm 0.6. IPTG (1 mM) was added to each 1 L culture for induction, and the 
incubation was continued at 37 oC for 6 hours more with concurrent shaking at 300 rpm. 
 
2.3 Protein Purification 
 After protein expression, the 1 L culture was transferred into 3 large centrifuge 
tubes and then centrifuged at 3000 xg for 20 min at 4 oC by using a floor centrifuge (J2-
21 centrifuge from Beckman). The media was discarded, and the cell pellets were stored 
in -20 oC freezer for subsequent usage. The frozen pellets were thawed at room 
temperature, and 10 ml of PBS was added into each tube. The cell pellets were 
resuspended, transferred into a 50 ml falcon tube, and incubated on ice for 10 minutes. 
Sonication was performed (Appendix A.4) using a 550 Sonic Dismembrator from Fisher 
Scientific. After sonication, the sample was cooled down on ice for 15 minutes. 
 
2.3.1 Inverse Transition Cycle (ITC) 
ELP-TEVG-TmAFP, ELP-TEVS-TmAFP, and ELP-TEV protease proteins were 
purified by ITC [52]. The cold spin and warm spin were defined by the transition 
temperature (Tt) of the ELP tagged protein: The cold spin was performed below the Tt, 
and the warm spin was performed above the Tt. Insoluble substances are separated with 
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the cold spins because ELP tagged protein is soluble in aqueous solution below the Tt. 
Soluble substances are separated with the use of warm spins because ELP tagged protein 
are insoluble in aqueous solution above the Tt. The protocol of ITC purification is 
described in Appendix (A.5).  
 
2.3.2 Cold finger purification 
For antifreeze proteins (ELP-TEVG-TmAFP and ELP-TEVS-TmAFP), active 
proteins can be purified by cold finger purification since antifreeze proteins bind to ice 
and become incorporated in the growing ice, while others are excluded. This general 
method for cold finger purification has been previously described (Figure 2.9) [74], and 
the protocol is reported in Appendix A.6. The entire cold finger purification was 
performed in a 4 oC room. The cold finger was connected with a temperature controlled 
water bath (VWR Scientific model 1156) filled with antifreezer. The temperature of the 
water bath was pre-set at -0.5 oC, and the cold finger was covered with a thin layer of ice 
in a double distilled water beaker filled with a piece of ice. The sonicated sample was 
diluted up to 80 ml with double distilled water added, and a magnetic stir bar was placed 
in the sample solution. The diluted protein solution was switched to a double distilled 
water beaker, and the ice covered cold finger was placed in the protein solution. The 
temperature was gradually lowered from -0.5 to -2.0 oC over 8 hours (i.e. -0.1°C / 30min) 
with stirring at 350 rpm. The sample solution (liquid fraction) was removed. Then the ice 
on the cold finger was set in a 1 oC water bath until it melted down and the collected 
solution is the ice fraction.  
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Figure 2.9. The schematic diagram of cold finger purification. (A) seeding the cold 
finger in cooled distilled water with a piece of ice; (B) A water filled beaker is replaced 
with sample beaker after thin ice layer is formed on the cold finger; (C) the cold finger is 
placed in sample solution; (D) the ice is growing until temperature reaches -2.0 oC; (E) 
the ice fraction containing the bound AFPs is collected [74]. Reprinted from Biochemical 
and Biophysical Research Communication, 300, Kuiper, M. J., Lankin, C., Gauthier, S. 
Y., Walker, V. K., and Davies, P. L. (2003), Purification of antifreeze proteins by 
adsorption to ice, 646, Copyright (2014), with permission from Elsevier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Cold finger purification apparatus. Figure was modified from the original 
figure with permission of Sen Bu. [73].  
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2.4 Characterization of Proteins 
To elucidate the protein, protein samples were loaded onto a 4-20 % Precise 
protein gel (Thermo Scientific) by using a SDS electrophoresis kit (Mini Protein 3 cell 
from BIO-RAD) at 100 V for 1 hour with BupHTM Tris-HEPES-SDS running buffer from 
Thermo Scientific. The protein gel was stained by using GelCodeBlue (Thermo 
Scientific) at room temperature for 2 hours, and then washed with double distilled water 
several times and double distilled water was added overnight as a destaining process. A 
scanner (Epson Perfection 1650) was used to scan and image the destained gel. 
 
2.4.1 Protein concentration measurements 
Protein concentration was calculated from absorbance at 280 nm wavelength 
using a calculating molecular extinction coefficient [76]. Absorbance was measured in a 
1cm diameter quartz cuvette using UV spectrophotometer (Biomate 3 from Thermo 
Scientific).   
 
2.4.2 Activity of TEV protease 
 ELP tagged TEV protease that is active can cleave at TEV protease cleavage sites, 
which were placed between the ELP tag and TmAFP. ELP tags of ELP-TEV protease, 
ELP-TEVG-TmAFP, and ELP-TEVS-TmAFP were identical to purified proteins by using 
the same temperature setting during ITC. The cleavage reaction by TEV protease was 
performed in PBS with an overnight incubation at 4 oC or 3 hours incubation at room 
temperature in the 1:5 concentration ratio of enzyme to substrate. After incubation, the 
reaction mixtures were characterized by SDS-PAGE. 
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2.4.3 Availability of TEV protease cleavage site 
ProTEV from Promega was used to measure the availability of the TEV protease 
cleavage site placed in between ELP and TmAFP. The 100 µl of reaction volume 
contained 5 µl ProTEV buffer, 1 µl 100 mM DTT (Promega), 2 µl Pro TEV plus 
protease, 20 μg fusion protein, and filled with nuclease free water up to a 100 μl total 
volume. The reaction mixture was incubated at 4 oC overnight or at 30 oC for 1 hour. 
After incubation, the reaction mixtures were loaded on protein gels. 
 
2.4.4 Activity of TmAFP 
  Activity of TmAFP as the target protein was observed by using cold finger 
purification as previously mentioned. The samples were loaded on protein gels. 
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CHAPTER III 
RESULTS AND DISCUSSION 
   
3.1 Synthesis of plasmid DNAs 
3.1.1 Synthesis of ELP-TEVG-TmAFP and ELP-TEVS-TmAFP 
 Plasmid DNA sequencing confirmed that the synthesis of ELP-TEVG-TmAFP 
and ELP-TEVS-TmAFP DNAs were accomplished in pET20b plasmids. The yellow 
highlighted sequences are ELP, the blue highlighted sequences are TEVG and TEVS, and 
the red highlighted sequences are TmAFP. 
 
 ELP[(GVGVP)20]-TEVG-TmAFP (5’ → 3’) 
ATGGGCCACGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCG
GGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGT
GTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGC
GTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTT
CCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTG
GGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGAAAACCTG
TACTTCCAGGGGCCGGGCTGGCCACAGTGCACCGGTGGTGCTGACTGCACCAGC
TGCACCGCTGCTTGCACCGGTTGCGGTAACTGCCCGAACGCTGTTACTTGCACT
AACAGCCAGCACTGCGTTAAAGCTACCACCTGCACCGGTAGCACCGACTGCAAC
ACCGCTGTTACCTGCACTAACTCTAAAGACTGCTTCGAAGCTCAGACCTGCACC
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GACTCTACCAACTGCTACAAAGCTACCGCTTGCACCAACTCTACCGGCTGCCCG
GGTCAC 
 
ELP[(GVGVP)20]-TEVS-TmAFP (5’ → 3’) 
ATGGGCCACGGCGTGGGTGTTCCGGGAGTAGGTGTCCCAGATGTGGGCGTACCG
GGCGTTGATGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGT
GTCCCAGATGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGC
GTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTT
CCTGGTGTCGGCGTGCCGAGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTG
GGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGAAAACCTG
TACTTCCAGTCGCCGGGCTGGCCACAGTGCACCGGTGGTGCTGACTGCACCAGC
TGCACCGCTGCTTGCACCGGTTGCGGTAACTGCCCGAACGCTGTTACTTGCACT
AACAGCCAGCACTGCGTTAAAGCTACCACCTGCACCGGTAGCACCGACTGCAAC
ACCGCTGTTACCTGCACTAACTCTAAAGACTGCTTCGAAGCTCAGACCTGCACC
GACTCTACCAACTGCTACAAAGCTACCGCTTGCACCAACTCTACCGGCTGCCCG
GGTCAC 
 
ELP[(GVGVP)40]-TEVG-TmAFP (5’ → 3’)  
ATGGGCCACGGCGTGGGTGTTCCGGGAGTAGGTGTCCCAGATGTGGGCGTACCG
GGCGTTGATGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGT
GTCCCAGATGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGC
GTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTT
CCTGGTGTCGGCGTGCCGAGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTG
GGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCG
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GGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGC
GTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGC
GTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTC
CCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTG
GGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCT
GGTGTCGGCGTGCCGGGCGTGGAAAACCTGTACTTCCAGGGGCCGGGCTGGCCA
CAGTGCACCGGTGGTGCTGACTGCACCAGCTGCACCGCTGCTTGCACCGGTTGC
GGTAACTGCCCGAACGCTGTTACTTGCACTAACAGCCAGCACTGCGTTAAAGCT
ACCACCTGCACCGGTAGCACCGACTGCAACACCGCTGTTACCTGCACTAACTCT
AAAGACTGCTTCGAAGCTCAGACCTGCACCGACTCTACCAACTGCTACAAAGCT
ACCGCTTGCACCAACTCTACCGGCTGCCCGGGTCAC 
 
ELP[(GVGVP)40]-TEVS-TmAFP (5’ → 3’) 
ATGGGCCACGGCGTGGGTGTTCCGGGAGTAGGTGTCCCAGATGTGGGCGTACCG
GGCGTTGATGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGT
GTCCCAGATGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGC
GTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTT
CCTGGTGTCGGCGTGCCGAGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTG
GGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCG
GGAGTAGGTGTCCCAGATGTGGGCGTACCGGGCGTTGATGTTCCTGGTGTCGGC
GTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGATGTGGGCGTACCGGGC
GTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTC
CCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGAGCGTG
GGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCT
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GGTGTCGGCGTGCCGGGCGTGGAAAACCTGTACTTCCAGTCGCCGGGCTGGCCA
CAGTGCACCGGTGGTGCTGACTGCACCAGCTGCACCGCTGCTTGCACCGGTTGC
GGTAACTGCCCGAACGCTGTTACTTGCACTAACAGCCAGCACTGCGTTAAAGCT
ACCACCTGCACCGGTAGCACCGACTGCAACACCGCTGTTACCTGCACTAACTCT
AAAGACTGCTTCGAAGCTCAGACCTGCACCGACTCTACCAACTGCTACAAAGCT
ACCGCTTGCACCAACTCTACCGGCTGCCCGGGTCAC 
 
Also, the corresponding amino acid sequences were obtained from the confirmed 
DNA sequences using DNA to protein translation [77]. The yellow highlighted sequences 
are ELP, the blue highlighted sequences are TEVG and TEVS, and the red highlighted 
sequences are TmAFP. 
 
ELP[(GVGVP)20]-TEVG-TmAFP)  
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVENL
YFQGPGWPQCTGGADCTSCTAACTGCGNCPNAVTCTNSQHCVKATTCTGSTDCN
TAVTCTNSKDCFEAQTCTDSTNCYKATACTNSTGCPGH 
 
ELP[(GVGVP)20]-TEVS-TmAFP  
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVENL
YFQSPGWPQCTGGADCTSCTAACTGCGNCPNAVTCTNSQHCVKATTCTGSTDCN
TAVTCTNSKDCFEAQTCTDSTNCYKATACTNSTGCPGH  
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ELP[(GVGVP)40]-TEVG-TmAFP  
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGV
PGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVENLYFQGPGWP
QCTGGADCTSCTAACTGCGNCPNAVTCTNSQHCVKATTCTGSTDCNTAVTCTNS
KDCFEAQTCTDSTNCYKATACTNSTGCPGH  
 
ELP[(GVGVP)40]-TEVS-TmAFP  
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGV
PGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVENLYFQSPGWP
QCTGGADCTSCTAACTGCGNCPNAVTCTNSQHCVKATTCTGSTDCNTAVTCTNS
KDCFEAQTCTDSTNCYKATACTNSTGCPGH 
 
3.1.2 Synthesis of ELP-TEV Protease 
The synthesis of the gene for ELP[(GVGVP)40]-TEV protease was successful. 
The DNA sequence of ELP[(GVGVP)40]-TEV protease was accomplished in pET20b 
plasmids: The yellow highlighted sequences are ELP and the green highlighted sequences 
are TEV protease. 
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ELP[(GVGVP)40]-TEV protease (5’ → 3’) 
ATGGGCCACGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCG
GGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGT
GTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGC
GTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTT
CCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTG
GGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCG
GGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGC
GTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGC
GTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTGGGTGTTCCGGGCGTAGGTGTC
CCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCTGGTGTCGGCGTGCCGGGCGTG
GGTGTTCCGGGCGTAGGTGTCCCAGGTGTGGGCGTACCGGGCGTTGGTGTTCCT
GGTGTCGGCGTGCCGGGCGTGGGAGAAAGCTTGTTTAAGGGGCCGCGTGATTAC
AACCCGATATCGAGCACCATTTGTCATTTGACGAATGAATCTGATGGGCACACA
ACATCGTTGTATGGTATTGGATTTGGTCCCTTCATCATTACAAACAAGCACTTG
TTTAGAAGAAATAATGGAACACTGTTGGTCCAATCACTACATGGTGTATTCAAG
GTCAAGAACACCACGACTTTGCAACAACACCTCATTGATGGGAGGGACATGATA
ATTATTCGCATGCCTAAGGATTTCCCACCATTTCCTCAAAAGCTGAAATTTAGA
GAGCCACAACGTGAAGAGCGTATCTGCCTTGTGACAACCAACTTCCAAACTAAG
AGCATGTCTAGCATGGTGTCAGACACTAGTTGCACATTCCCTTCATCTGATGGC
ATATTCTGGAAGCATTGGATTCAAACCAAGGATGGGCAGTGTGGCAGTCCATTA
GTATCAACTAGAGATGGGTTCATTGTTGGTATACACTCAGCATCGAATTTCACC
AACACAAACAATTATTTCACAAGCGTGCCGAAAAACTTCATGGAATTGTTGACA
AATCAGGAGGCGCAGCAGTGGGTTAGTGGTTGGCGATTAAATGCTGACTCAGTA
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TTGTGGGGGGGCCATAAAGTTTTCATGGTGAAACCTGAAGAGCCTTTTCAGCCA
GTTAAGGAAGCGACTCAACTCATGAAT 
 
 Also, the corresponding amino acid sequences were determined from DNA 
sequences using DNA to protein translation [77]. The yellow highlighted sequences are 
ELP and the green highlighted sequences are TEV protease. 
 
ELP[(GVGVP)40]-TEV protease  
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGV
PGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGESLFKGPRDY
NPISSTICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRNNGTLLVQSLHGVFK
VKNTTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFREPQREERICLVTTNFQTK
SMSSMVSDTSCTFPSSDGIFWKHWIQTKDGQCGSPLVSTRDGFIVGIHSASNFT
NTNNYFTSVPKNFMELLTNQEAQQWVSGWRLNADSVLWGGHKVFMVKPEEPFQP
VKEATQLMN  
 
 3.2 Protein Expression 
3.2.1 Protein expression of ELP-TEVG-TmAFP and ELP-TEVS-TmAFP 
 Since ELP and TmAFP were previously expressed independently in our lab, the 
protein expressions of ELP-TEVG-TmAFP and ELP-TEVS-TmAFP were not 
investigated. The molecular weight of ELP-TEVG-TmAFP and ELP-TEVS-TmAFP were 
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calculated based on the amino acid sequence using the Protein Information Resource 
[78]. 
 
Table 3.1. The expected molecular weight of ELP-TEVG-TmAFP and ELP-TEVS-
TmAFP. 
Sample Molecular Weight 
ELP[(GVGVP)20]-TEVG-TmAFP 18.3 kDa  
ELP[(GVGVP)20]-TEVS-TmAFP 18.4 kDa 
ELP[(GVGVP)40]-TEVG-TmAFP 26.5 kDa  
ELP[(GVGVP)40]-TEVS-TmAFP 26.6 kDa  
  
3.2.2 Protein expression of ELP[(GVGVP)40]-TEV protease 
The expected molecular weight of ELP[(GVGVP)40]-TEV protease was 
calculated from Protein Information Resource [78] and it is 43.7 kDa. The protein 
expression of ELP[(GVGVP)40]-TEV protease was investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. B-PER of ELP[(GVGVP)40]-TEV protease. Lane 1 to 3 were an insoluble 
fraction, lane 4 was blank, and lane 5 to 7 were a soluble fraction. Lane 1 and 5 were 
collected before induction, lane 2 and 6 were collected at 3 h after induction, and lane 3 
and 7 were collected at 6 h after induction. 
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As expression time lapsed after induction, the protein bands at 43.7 kDa became 
more intense (darker) in both the insoluble and soluble fractions. This implies that 
ELP[(GVGVP)40]-TEV protease was expressed as both insoluble and soluble protein. 
The recombinant TEV protease has been reported to be insoluble in aqueous solution 
[71], while ELP is known to facilitate the increase in solubility of fusion proteins in 
aqueous solutions [12]. However, it seemed that ELP might not completely make 
ELP[(GVGVP)40]-TEV protease soluble in aqueous solution.    
 
3.3 Protein Purification 
3.3.1 ITC Purification 
ELP-TEVG-TmAFP, ELP-TEVS-TmAFP, and ELP-TEV protease were purified 
by ITC purification. 
(A)                                                                      (B) 
                                                                                                                                               
 
 
 
 
 
 
 
 
 
 
Figure 3.2. (A) ITC purification of ELP[(GVGVP)20]-TEVG-TmAFP (18.3 kDa) 
and  (B) ITC purification of ELP[(GVGVP)20]-TEVS-TmAFP (18.4 kDa). Lane 1 is 
the molecular weight marker, lane 2 is the first cold centrifuge pellet, lane 3 is the first 
warm centrifuge supernatant, lane 4 is the second cold centrifuge pellet, lane 5 is the 
second warm centrifuge supernatant and lane 6 is the third cold centrifuge supernatant, 
which is the final purified product.   
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Figure 3.3. ITC purification of ELP[(GVGVP)40]-TEVG-TmAFP : 26.5 kDa and ITC 
purification of ELP[(GVGVP)40]-TEVS-TmAFP : 26.6 kDa. Lane 1 is the molecular 
weight marker, lane 7 is blank, lane 2 and 8 are the first cold centrifuge pellet, lane 3 and 
9 are the first warm centrifuge supernatant, lane 4 and 10 are the second cold centrifuge 
pellet, lane 5 and 11 are the second warm centrifuge supernatant and lane 6 and 12 are the 
third cold centrifuge supernatant, which is the final purified product.  
 
The protein concentrations by ITC purification were measured. 
Table 3.2. The protein concentration by ITC purification.  
  
 
 
 
 Sample C (M) Yield (mg) in 1 L 
ELP[(GVGVP)20]-TEVG-TmAFP 6.79x10-5 3.74 
ELP[(GVGVP)20]-TEVS-TmAFP 1.08x10-4 5.59 
ELP[(GVGVP)40]-TEVG-TmAFP 1.81x10-4 14.41 
ELP[(GVGVP)40]-TEVs-TmAFP 2.52x10-4 20.08 
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Figure 3.4. ITC purification of ELP[(GVGVP)40]-TEV protease : 43.7 kDa. Lane 1 is 
the molecular weight marker, lane 2 is the first cold centrifuge pellet, lane 3 is the first 
warm centrifuge supernatant, lane 4 is the second cold centrifuge pellet, lane 5 is the 
second warm centrifuge supernatant, lane 6 is the third cold centrifuge pellet, and lane 7 
is the third cold centrifuge supernatant, which is the final purified product.  
 
ELP-TEVG-TmAFP and ELP-TEVS-TmAFP were successfully purified by using 
ITC purification, while ELP[(GVGVP)40]-TEV protease was not successfully purified by 
ITC purification. Because the optimal temperature of TEV protease is 30 oC [15], it 
seemed that ELP[(GVGVP)40]-TEV protease might be denatured during ITC purification 
above its optimal temperature (Tt of ELP[(GVGVP)40]-TEV protease is around 40 oC). 
ELP[(GVGVP)40]-TEV protease might need an alternative purification method(s) or 
additional purification steps. 
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3.4 Protein Characterization 
3.4.1 The functionality of TEV protease cleavage site; TEV G and TEV S 
With ProTEV protease from Promega, which is 50 kDa in size, the ability to cleave at the 
TEV protease cleavage sites between ELP and TmAFP were examined. ELP-TEVG-
TmAFP and ELP-TEVS-TmAFP were examined for this reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. The functionality test of TEV protease cleavage sites: TEVG and TEVS : 
ELP[(GVGVP)20]-TEVG-TmAFP : 18.3 kDa and ELP[(GVGVP)20]-TEVS-TmAFP : 18.4 
kDa. Lane 1 and 3 are ELP fusion protein only and lane 2 and 4 are samples of a mixture 
solution of ELP fusion protein and ProTEV that were incubated at room temperature for 
3 hours. Lane 1 and 3 are samples that were intentionally kept at the same concentration 
as the original stock.  
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Figure 3.6. The functionality test of TEV protease cleavage sites; TEVG and TEVS : 
ELP[(GVGVP)40]-TEVG-TmAFP : 26.5 kDa and ELP[(GVGVP)40]-TEVS-TmAFP : 26.6 
kDa. Lane 1 and 3 are ELP fusion protein only, lane 2 and 4 are samples of a mixture 
solution of ELP fusion protein and ProTEV that were incubated at room temperature for 
3 hours. Lane 1 and 3 are samples that were intentionally kept at the same concentration 
as the original stock.  
 
 
 The TEV cleavage reactions were not observed between ELP[(GVGVP)20] and 
TmAFP or between ELP[(GVGVP)40] and TmAFP because the size of ProTEV and ELP 
tagged TmAFP fusion proteins were only observed on protein gel.  
 
3.4.2 The activity of TmAFP 
Cold finger purification was performed to observe the activity of TmAFP.  
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Figure 3.7. Cold finger purification. Lane 5 and 9 are blank. Lane 2, 6, and 10 are 
diluted unpurified proteins. Lane 3, 7, and 11 are liquid fraction after cold finger 
purification. Lane 4, 8, and 12 are ice fraction after cold finger purification. 
 
There were no fusion proteins observed on the protein gel at His-eGFP-TmAFP, 
19.6 kDa, ELP[(GVGVP)40]-TEVG-TmAFP, 26.5 kDa, and ELP[(GVGVP)40]-TEVs-
TmAFP, 26.6 kDa. The paucity of protein expressions was observed several times from 
the bacterial cultures obtained from frozen stocks which had previously been stored in a -
80 oC freezer that became malfunctional. After the DNA sequences of fusion proteins 
were verified, the multiple expression of fusion proteins were performed. However, there 
were no fusion proteins expressed. It may need re-transformation into newer host 
competent cells. 
 
 
       
58 
 
 
 
CHAPTER IV 
CONCLUSION 
 
 In this research, elastin-like polypeptide (ELP) tags were used to implement a 
strategy to purify recombinant Tenebrio molitor antifreeze protein (TmAFP) from E. coli. 
This purification method would allow an efficient purification method compared to other 
purification methods for recombinant TmAFP.  
 In order to implement this approach, we successfully prepared genes encoding 
TmAFP and TEV protease with N-terminal ELP fusion tags. The TmAFP constructs 
included a TEV cleavage site for removal of the ELP fusion tag. TEV cleavage sites and 
ELP tag DNAs were designed and successfully added to the N-terminus of TmAFP 
sequentially. ELP[(GVGVP)40] tag DNA was successfully added to the N-terminus of 
TEV protease while ELP[(GVGVP)20] tag DNA was not successfully added to the N-
terminus of TEV protease. 
There was mixed success in the expression and purification of the constructs. ELP 
tagged fusion proteins were successfully expressed at least once. ELP tagged fusion 
TmAFPs were successfully purified by using ITC. However, ELP tagged fusion TmAFPs 
were not successfully purified by cold finger purification because of failed expression. 
ELP tagged fusion TEV protease was not successfully purified by ITC purification 
because ELP[(GVGVP)40]-TEV protease showed poor solubility in an aqueous solution. 
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The purification process may need to be improved to increase its solubility or an 
alternative purification method(s) may need to be used. The TEV protease cleavage 
reaction was not observed between ELP and TmAFP by ProTEV from Promega. 
In conclusion, the genetic engineering of ELP tagged fusion proteins was overall 
successful. However, the expression and purification process need to be improved. ELP 
tags were functional through ITC purification and appear to aid in target protein 
purification. The functionality of the TEV protease cut site was not observed, but because 
of a lack of a positive control this conclusion is not certain. The activity of TmAFP was 
not measurable because of negative results from poor protein expression.  
In the future, this purification method may be applicable for scale-up mass 
production of recombinant TmAFP. However, the activity of ELP tagged TEV protease 
needs to be measured. The activity of TmAFP without an ELP tag after TEV protease 
cleavage reaction needs to be measured as well. The comparison of several factors such 
as activity, yield, efficient purification, and solubility of ELP tagged and untagged TEV 
protease and TmAFP need to be considered. These factors should be further investigated 
in subsequent experiments.  
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A.1 The protocol of DNA annealing 
1. The 50 µl of reaction mixture, which contains 4 µl of forward primer, 4 µl of 
reverse primer, 21 µl of Quick ligation buffer (New England Biolabs), and 21 µl 
of nuclease free water (New England Biolabs), are added into PCR tubes. 
2. Place PCR tubes in a thermo cycler (Thermo Electron Corp.) 
- The sample cycle C27 is selected. 
 
The description of sample cycle C27 
- Heat up to 95 oC for 5 min and cool down to 25 oC over 70 cycles. 
- Keep at 4 oC for 55 minutes  
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A.2 The protocol of 1.5% agarose gel preparation for DNA sample gel 
electrophoresis  
1. Add 75 ml 1X TAE buffer and 1.125 g agarose (molecular biology grade) in a 
beaker. 
2. Stir (or heat up) mixture until a clean solution is formed. 
3. If heat is applied, allow it to cool down. 
4. Add 7.5 μl ethidium bromide and mix well by stirring gently at vent hood. 
5. Pour the solution into gel casting cassette.  
6. Place the combs for sample loads.  
7. Allow it dry at room temperature. 
8. Remove the combs. 
9. Place the gel in a gel tank.  
10. Pour 1X TAE buffer in a gel tank until the gel is submerged. 
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A.3 The protocol of PCR  
The 25 μl of PCR for screening:  
1. The 25 µl of PCR mixture, which contains 12.5 µl PCR master mix (Promega), 
2.5 µl T7 forward primer, 2.5 µl T7 reverse primer, 6.5 µl nuclease free water, 
and 1 µl plasmid DNA, is added into PCR tubes. 
2. Place PCR tubes in a thermo cycler (Thermo Electron Corp.).  
- The sample cycle C16 is selected. 
 
The 100 μl of PCR for priming out and amplification 
1. The 100 µl of PCR mixture, which contains 50 µl PCR master mix, 26 µl 
nuclease free water, 10 µl forward primer, 10 µl reverse primer, and 4 µl plasmid 
DNA, is added into PCR tubes. 
2. Place PCR tubes in a thermo cycler (Thermo Electron Corp.).  
- The sample cycle C16 is selected. 
 
The description of sample cycle C16 
- 2 minutes at 95 °C for melting the DNA.  
- 30 cycles of:  
- 1 min at 72 °C for annealing the primers to the DNA.  
- 30 seconds at approximately 5 °C below the melting point of the primers
 for primer extension.  
- 1 minute at 72 °C for primer extension. 
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- Refrigeration at 4 °C for several hours until the sample is removed from 
the thermocycler. 
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A.4 The protocol of sonication 
 1. Resuspend the pellets with added 10 ml of PBS. 
2. Transfer the resuspended samples into a 50 ml falcon tube. 
3. Cool down on ice for 15 minutes. 
4. Place the falcon tube into a beaker containing ice and water. 
5. Before sonication, clean the probe of the sonicator with ethanol and distilled 
water. 
6. Place the probe of the sonicator in the faclon tube. 
7. Turn on the sonicator. 
8. Press the Tune key, and turn the amplitude control knob to the settings of 3, 6, 
and 10. At each setting, adjust the amplitude control knob to keep the bar graph 
less than 50 % in order to maintain a minimum meter reading less than 10 %.  
9. Press the stop key and turn the amplitude control knob back to zero. 
10. After sonication, clean the probe of the sonicator with ethanol and distilled 
water again. 
11. Cool down the falcon tube on ice for 20 min. 
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A.5 The protocol of ITC purification 
1. The sonicated sample is transferred into a centrifuge tube for the cold 
centrifugation. 
2. Cold centrifugation 
 - Place a centrifuge tube in rotor and balance a centrifuge tube. 
- Tighten the lid and set the centrifuge for 20 minutes at 20,000 xg.   
3. The supernatant is descanted into a centrifuge tube for the warm centrifugation. 
4. Incubate the sample at above Tt of the ELP tagged protein for 2 hours. 
5. Warm centrifugation 
 - Place a centrifuge tube in rotor and balance a centrifuge tube. 
- Tighten the lid and set the centrifuge for 20 minutes at 20,000 xg.   
6. The warm supernatant is discarded, a warm pellet is resuspended with added 5 
ml of PBS on ice.  
7. Step 2-5 is repeated. 
8. The warm supernatant is discarded, a warm pellet is resuspended with added 3 
ml of PBS on ice.   
9. Final cold spin is performed, and the cold supernatant is collected in a 50 ml 
falcon tube as it is the final protein solution. 
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A.6 The protocol of Cold finger purification 
1. Set the water bath to -0.5 oC. 
2. Place the cold finger in a cooled water beaker until a thin layer of ice is formed 
on the cold finger. 
3. Replace a water beaker to sample solution glass, and place a magnetic stir bar 
in sample solution. 
4. Lower temperature gradually from -0.5 to -2.0 oC for 8 hours (i.e. -0.1 °C 
/30min) with stirring 350 rpm. 
5. Wash ice on the cold finger with distilled water and replace sample solution 
beaker into an empty beaker. 
6. Harvest sample beaker, which is the liquid fraction 
7. Set the water bath to 1 °C and harvest the ice on the cold finger until it detaches 
from the cold finger.  
8. Let the ice melt down and collect the solution, which is the ice fraction. 
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A.7 The bacterial protein extraction reagent, B-PER, protocol 
1. Collect 1 ml of bacterial cells in 1.5 ml microcentrifuge tubes before and after 
induction as expression time lapses. 
2. Centrifuge bacterial cells at 14,000 rpm in a microcentrifuge for 5 minutes and 
discard the supernatant. 
3. Re-suspend the bacterial cell pellet in 100 µl B-PER reagent by vigorously 
vortexing. 
4. Centrifuge at 14,000 rpm in a microcentrifuge for 5 minutes and collect the 
supernatant (soluble fraction).  The pellet is considered to be the insoluble 
fraction.  
5. Re-suspend the pellet in 100 µl B-PER reagent by vigorously vortexing again. 
6. Use 15 µl of both the soluble and insoluble fraction for SDS-PAGE. 
 
